[
  {
    "ts": null,
    "headline": "Juvenile Idiopathic Arthritis Market is Expected to Expand at a Healthy Growth Rate of 5.6% During the Forecast Period (2026-2036) | DelveInsight",
    "summary": "Recently published Juvenile Idiopathic Arthritis Market Insights report includes a comprehensive understanding of current treatment practices, juvenile idiopathic arthritis emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].",
    "url": "https://finnhub.io/api/news?id=b0c58f001c5ca4ec5034dbfc4437e6038d7d8c1d835bd55d007248a2ea1e1bae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771367460,
      "headline": "Juvenile Idiopathic Arthritis Market is Expected to Expand at a Healthy Growth Rate of 5.6% During the Forecast Period (2026-2036) | DelveInsight",
      "id": 139127384,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Recently published Juvenile Idiopathic Arthritis Market Insights report includes a comprehensive understanding of current treatment practices, juvenile idiopathic arthritis emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].",
      "url": "https://finnhub.io/api/news?id=b0c58f001c5ca4ec5034dbfc4437e6038d7d8c1d835bd55d007248a2ea1e1bae"
    }
  },
  {
    "ts": null,
    "headline": "Iberdomide FDA Milestone Puts Fresh Focus On Bristol Myers Squibb Hematology",
    "summary": "FDA accepts New Drug Application for iberdomide in relapsed or refractory multiple myeloma. Iberdomide is being evaluated in combination with standard treatment for patients who have already received prior therapies. The FDA grants Breakthrough Therapy designation to the iberdomide combination, aiming to speed development and review. The update marks a new step for Bristol-Myers Squibb's hematology pipeline and could be relevant for the NYSE:BMY hematology franchise. Bristol-Myers Squibb,...",
    "url": "https://finnhub.io/api/news?id=26d79c5fcd718b62e50a3509fab26b6c96cd092cd491f83df1d544f0b0568254",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771348423,
      "headline": "Iberdomide FDA Milestone Puts Fresh Focus On Bristol Myers Squibb Hematology",
      "id": 139125176,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "FDA accepts New Drug Application for iberdomide in relapsed or refractory multiple myeloma. Iberdomide is being evaluated in combination with standard treatment for patients who have already received prior therapies. The FDA grants Breakthrough Therapy designation to the iberdomide combination, aiming to speed development and review. The update marks a new step for Bristol-Myers Squibb's hematology pipeline and could be relevant for the NYSE:BMY hematology franchise. Bristol-Myers Squibb,...",
      "url": "https://finnhub.io/api/news?id=26d79c5fcd718b62e50a3509fab26b6c96cd092cd491f83df1d544f0b0568254"
    }
  },
  {
    "ts": null,
    "headline": "Can BMY's Growth Portfolio Counter Legacy Drugs Decline in 2026?",
    "summary": "BMYs 2025 results highlight a shifting revenue mix as 17% growth in newer drugs offsets legacy declines, with more erosion expected in 2026.",
    "url": "https://finnhub.io/api/news?id=c0c5402bb35ebe74db18d1c27dbe8af06ca7854abe23e2dd188f480f5e69a830",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771340400,
      "headline": "Can BMY's Growth Portfolio Counter Legacy Drugs Decline in 2026?",
      "id": 139125079,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "BMYs 2025 results highlight a shifting revenue mix as 17% growth in newer drugs offsets legacy declines, with more erosion expected in 2026.",
      "url": "https://finnhub.io/api/news?id=c0c5402bb35ebe74db18d1c27dbe8af06ca7854abe23e2dd188f480f5e69a830"
    }
  },
  {
    "ts": null,
    "headline": "U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma",
    "summary": "PRINCETON, N.J., February 17, 2026--U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Relapsed or Refractory Multiple Myeloma",
    "url": "https://finnhub.io/api/news?id=a7ac930555b71c548abe3ff5a4f4f63ace72e32feeb6f3d8c45b5e043736b069",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771329540,
      "headline": "U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma",
      "id": 139122231,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., February 17, 2026--U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Relapsed or Refractory Multiple Myeloma",
      "url": "https://finnhub.io/api/news?id=a7ac930555b71c548abe3ff5a4f4f63ace72e32feeb6f3d8c45b5e043736b069"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Announces FDA Priority Review And Breakthrough Therapy Designation For Iberdomide Combination Therapy In Relapsed Or Refractory Multiple Myeloma",
    "summary": "Iberdomide has the potential to be the first approved CELMoD agentThe U.S. FDA has granted Breakthrough Therapy Designation and Priority Review for this indication and assigned a target action date of August 17, 2026",
    "url": "https://finnhub.io/api/news?id=e92c56925d6685af23467de531c8c4e78915c044f2108baf8fd46c62693c2cf9",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771315663,
      "headline": "Bristol Myers Squibb Announces FDA Priority Review And Breakthrough Therapy Designation For Iberdomide Combination Therapy In Relapsed Or Refractory Multiple Myeloma",
      "id": 139123322,
      "image": "",
      "related": "BMY",
      "source": "Benzinga",
      "summary": "Iberdomide has the potential to be the first approved CELMoD agentThe U.S. FDA has granted Breakthrough Therapy Designation and Priority Review for this indication and assigned a target action date of August 17, 2026",
      "url": "https://finnhub.io/api/news?id=e92c56925d6685af23467de531c8c4e78915c044f2108baf8fd46c62693c2cf9"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie: Dominating Immunology While Building Oncology Upside",
    "summary": "The total net revenues of AbbVie's Rinvoq and Skyrizi were about $25.87 billion in 2025, up 46.2% from 2024. Read why ABBV stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=d0d43a6522bc4e441a8332fdd53d2e63617ad866a0c0b56eb5e1f8a2822d2878",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771290687,
      "headline": "AbbVie: Dominating Immunology While Building Oncology Upside",
      "id": 139119790,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1398519163/image_1398519163.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "The total net revenues of AbbVie's Rinvoq and Skyrizi were about $25.87 billion in 2025, up 46.2% from 2024. Read why ABBV stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=d0d43a6522bc4e441a8332fdd53d2e63617ad866a0c0b56eb5e1f8a2822d2878"
    }
  }
]